Metastatic Urothelial Carcinoma Pipeline Insight By DelveInsight

August 14 16:21 2020
Metastatic Urothelial Carcinoma Pipeline Insight By DelveInsight

(Albany, US) DelveInsight has launched a new report on  Metastatic Urothelial Carcinoma Pipeline

 

Metastatic Urothelial Carcinoma Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Metastatic Urothelial Carcinoma market. A detailed picture of the Metastatic Urothelial Carcinoma pipeline landscape is provided, which includes the disease overview and Metastatic Urothelial Carcinoma treatment guidelines. The assessment part of the report embraces in-depth Metastatic Urothelial Carcinoma commercial assessment and clinical assessment of the Metastatic Urothelial Carcinoma pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Urothelial Carcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Metastatic Urothelial Carcinoma starts when cells that make up the urinary bladder becomes cancerous. Bladder neoplasms can arise from any of the four bladder wall layers. They are broadly classified as either epithelial or non-epithelial (mesenchymal), with over 95% being epithelial. Epithelial tumors with differentiation toward normal urothelium are urothelial/ urinary carcinoma (UC). Other types of bladder neoplasms, namely, squamous cell carcinoma, adenocarcinoma, small cell carcinoma and sarcoma account for 2–5% of bladder neoplasms.

 

 

 

Request for free sample page: – https://www.delveinsight.com/sample-request/metastatic-urothelial-carcinoma-epidemiology-forecast

 

Metastatic Urothelial Carcinoma of pipeline development activities

The report provides insights into:

  • All of the companies that are developing therapies for the treatment of Metastatic Urothelial Carcinoma with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Metastatic Urothelial Carcinoma treatment.
  • Metastatic Urothelial Carcinoma key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Metastatic Urothelial Carcinoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc. 

 

Metastatic Urothelial Carcinoma Pipeline

 

Metastatic Urothelial Carcinoma pipeline possesses several potential drugs that are expected to be launched in the near future. Ramucirumab (Eli Lilly), Infigratinib (QED Therapeutics) are currently in phase III stage of development followed by Rogaratinib (Bayer) in phase II/III developmental stage and Pemigatinib (Incyte Corporation), Sacituzumab govitecan (Immunomedics), NKTR-214 (Nektar Therapeutics/Bristol-Myers Squibb), RX-3117 (Rexahn Pharmaceuticals) in phase II clinical stage.

 

Eli Lilly’s Ramucirumab is a human monoclonal antibody (IgG1) that works against vascular endothelial growth factor receptor 2 (VEGFR2) and is administered intravenously. On binding to VEGFR2, Ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signaling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, the drug binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. In April 2018, the company published results from its phase III trial of ramucirumab (Cyramza) in combination with docetaxel in patients with locally advanced or unresectable or metastatic UC. The RANGE study met its primary endpoint, showing that progression-free survival (PFS) significantly improved but the failed to improve overall survival of the patients.

 

Infigratinib is an orally administered, ATP-competitive, FGFR1-3 tyrosine kinase inhibitor in development for the treatment of patients with FGFR-driven diseases, including cholangiocarcinoma (bile duct cancer), urothelial carcinoma (bladder cancer), and achondroplasia, a bone growth disorder in children. Infigratinib is not chemotherapy. QED Therapeutics holds worldwide rights to infigratinib to evaluate its safety and efficacy for multiple FGFR-driven diseases. Currently, the drug is in phase III clinical developmental trial for the adjuvant treatment of subjects with invasive UC with susceptible FGFR3 mutations. In May 2020, the company claimed that it will present data at the American Society of Clinical Oncology 2020 Virtual Scientific Program showing clinical advancement for infigratinib, in both urothelial carcinoma and cholangiocarcinoma (CCA).

 

Metastatic Urothelial Carcinoma Report Scope

  • The Metastatic Urothelial Carcinoma report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Metastatic Urothelial Carcinoma across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Metastatic Urothelial Carcinoma therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Metastatic Urothelial Carcinoma research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Metastatic Urothelial Carcinoma.

 

Marketed drugs included in the report

  • Keytruda: Merck
  • Opdivo: Bristol-Myers Squibb
  • Tecentriq: Genentech
  • Bavencio: Merck
  • Imfinzi: AstraZeneca
  • Balversa: Janssen
  • Mitomycin gel (Jelmyto): UroGen Pharma

 

Emerging drugs included in the report

  • Ramucirumab: Eli Lilly and Company
  • Infigratinib: QED Therapeutics
  • Rogaratinib: Bayer
  • Pemigatinib: Incyte Corporation
  • Sacituzumab govitecan (IMMU-132): Immunomedics
  • Bempegaldesleukin (NKTR-214): Nektar Therapeutics/Bristol-Myers Squibb
  • RX-3117: Rexahn Pharmaceuticals
  • ACP-196: Acerta Pharma
  • IPI-549: Infinity Pharma

 

Download free sample page: –   https://www.delveinsight.com/sample-request/metastatic-urothelial-carcinoma-epidemiology-forecast

 

Table of content

 

1. Report Introduction

2. Metastatic Urothelial Carcinoma 

3. Metastatic Urothelial Carcinoma Current Treatment Patterns

4. Metastatic Urothelial Carcinoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Metastatic Urothelial Carcinoma Late Stage Products (Phase-III)

7. Metastatic Urothelial Carcinoma Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Metastatic Urothelial Carcinoma Discontinued Products

13. Metastatic Urothelial Carcinoma Product Profiles

14. Metastatic Urothelial Carcinoma Key Companies

15. Metastatic Urothelial Carcinoma Key Products

16. Dormant and Discontinued Products

17. Metastatic Urothelial Carcinoma Unmet Needs

18. Metastatic Urothelial Carcinoma Future Perspectives

19. Metastatic Urothelial Carcinoma Analyst Review  

20. Appendix

21. Report Methodology

22. About DelveInsight

 

Related Reports

 

Metastatic Urothelial Carcinoma Market Insights, Epidemiology and Market Forecast 2030

Metastatic Urothelial Carcinoma Epidemiology Forecast 2030

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/